Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 4,063 put options on the stock. This represents an increase of 2,362% compared to the average daily volume of 165 put options.
Wall Street Analysts Forecast Growth
A number of analysts have commented on XENE shares. StockNews.com cut Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday. Royal Bank of Canada reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating and a $67.00 price objective for the company. Finally, William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $57.38.
Read Our Latest Research Report on XENE
Xenon Pharmaceuticals Stock Performance
Shares of NASDAQ XENE traded up $1.23 during midday trading on Monday, reaching $30.63. 2,250,985 shares of the stock were exchanged, compared to its average volume of 413,731. The stock has a market capitalization of $2.34 billion, a P/E ratio of -10.86 and a beta of 1.21. The company has a 50 day simple moving average of $36.71 and a 200 day simple moving average of $39.35. Xenon Pharmaceuticals has a twelve month low of $27.54 and a twelve month high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05. On average, research analysts expect that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.
Insider Activity at Xenon Pharmaceuticals
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. This represents a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.52% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in shares of Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock valued at $38,456,000 after acquiring an additional 905,129 shares during the period. Barclays PLC lifted its stake in Xenon Pharmaceuticals by 1,275.5% during the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock worth $590,000 after purchasing an additional 13,903 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Xenon Pharmaceuticals by 12.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company's stock worth $9,350,000 after purchasing an additional 26,235 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Xenon Pharmaceuticals by 177.7% during the fourth quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company's stock worth $1,529,000 after buying an additional 24,956 shares during the period. Finally, State Street Corp raised its holdings in shares of Xenon Pharmaceuticals by 13.2% in the 3rd quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company's stock valued at $11,004,000 after buying an additional 32,701 shares during the period. Institutional investors and hedge funds own 95.45% of the company's stock.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
